CBL-514 Phase 3: SUPREME-01 and SUPREME-02
As of this November 11, 2026 review, Caliway reports that both SUPREME-01 and SUPREME-02 are advancing in its pivotal CBL-514 program. A trial starting enrollment does not mean its outcomes are known or the candidate has marketing approval.
The verified development update
Caliwayβs October 29 announcement reports that SUPREME-02, also called CBL-0302, began enrollment alongside the ongoing SUPREME-01 program. The sponsor describes a randomized, double-blind, placebo-controlled study of abdominal subcutaneous fat reduction, with approximately 320 participants planned for SUPREME-02.[1]
The word βplannedβ belongs with the enrollment figure. Target enrollment is a design feature, while actual enrollment is an observed count. A research timeline should keep those separate.
Milestones have different meanings
| Milestone | What it establishes |
|---|---|
| Permission to proceed | The study may move forward under its authorization |
| Enrollment begins | Recruitment activity has started |
| Primary completion | Collection for the primary endpoint reaches its defined completion |
| Results reported | Data and analyses can be evaluated |
| Marketing decision | A separate regulatory decision has been made |
The FDAβs IND explanation describes the framework for investigational studies; it is distinct from a marketing application.[2]
How to follow the program without overstating it
For each update, retain the trial identifier, publication date, current status and the sourceβs exact distinction between actual and anticipated events. Cross-check the registry when available. If a press release and a registry differ, record the discrepancy and their update dates rather than choosing the more optimistic version.
Future result dates are forecasts. Do not turn them into guaranteed release dates in evergreen copy. Likewise, a favorable earlier-phase result is a reason to study the question further, not the result of the upcoming trial.
This article is a dated development reference. It does not predict approval, market availability or a clinical outcome from a separately supplied research product.
Frequently asked questions
Does pivotal mean approved?
No. It describes the intended role of a study in development; approval is a separate decision.
Are enrollment targets final participant counts?
No. Planned enrollment and the number actually enrolled must be reported separately.
CBL-514 product and documentation
Review the current format and pack choices, then match the supplied lot to its documentation. No batch-specific identity, purity or content result is asserted in this article.
